Zura Bio Announces Participation in June 2024 Investor Conferences

2024-05-29

免疫疗法临床2期

HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor conferences in June. Conference Details: Event: Jefferies Global Healthcare Conference Details: Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will participate in one-on-one meetings on Thursday, June 6, 2024, in New York, NY. Event: Oppenheimer Novel Targets in Immunology Summit Details: Robert Lisicki, Chief Executive Officer, will participate in a “Novel Immunological Mechanisms for Dermatological Disorders” panel discussion and one-on-one meetings on Monday, June 24, 2024, in New York, NY. ABOUT ZURA BIO Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. View source version on businesswire.com: Contacts Megan K. Weinshank Head of Investor Relations ir@zurabio.com Lee M. Stern Meru Advisors lstern@meruadvisors.com Source: Zura Bio Limited View this news release online at:

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构